Our Mission since 1899 is to heal, to discover and to educate as a preeminent healthcare institution. We serve by providing the best integrated and innovative care for patients and their families; by understanding and finding cures for the diseases we research; and by educating and training the next generation of healthcare professionals to be leaders in medicine and science. Recent achievements: 1) On April 8th, 2010, National Jewish Health was recognized by the Colorado House and Senate for our vital role in serving the health needs of Colorado citizens and the opening of our Lung Cancer Center. 2) Since 1998, U.S. News & World Report has ranked National Jewish Health the #1 respiratory hospital in the nation. 3)Thomson Scientific has ranked National Jewish Health among the 25 most influential research institutions in the world in its areas of focus. 4)National Jewish Health has been named the second best place in the United States for “postdocs” to work, as ranked by The Scientist.
Featured Startups and Technologies
Taiga Biotechnologies, Inc.
Taiga Biotechnologies, Inc. is a privately held developer of novel therapies for complex diseases including cancers, infectious agents such as HIV and influenza, and hematologic conditions. Each of the company’s core programs derives from Taiga’s proprietary technology platform for conditionally immortalized adult hematopoetic stem cells (HSCs). The company’s initial focus includes an immune response enhancer for improving vaccination strategies for infectious diseases and cancer and the development of a universal donor blood stem cell line for clinical use. Copyright Taiga Biotechnologies, Inc.
Aeolus Pharmaceuticals, Inc.
Aeolus Pharmaceuticals is developing small molecule catalytic antioxidants that has shown the ability to scavenge a broad range of reactive oxygen species. James Crapo, MD, and Brian Day, PhD, of National Jewish Health are inventors on the intellectual property underlying this discovery, as well other investigators at Duke University.
Vistagen Therapeutics, Inc.
VistaGen Therapeutics, Inc. is a biotechnology company focused on using proprietary stem cell technologies for drug rescue. Their integrated stem cell biology platform, Human Clinical Trials in a Test Tube (TM), is designed to provide an early indication, or prediction, of the potential cardiac toxicity of drug candidates before they are ever tested in humans. Their stem cell technology is designed to identify new, safer, variants of promising drug candidates. These candidates have been previously “put on the shelf” by pharmaceutical companies due to toxicity concerns, despite positive efficacy data signaling their potential therapeutic benefits. Their goal is to build a diverse drug pipeline of “drug rescue variants” that are as effective as the original drug candidates but without the toxicity that caused them to be put on the shelf in the first place. Copyright Vistagen Therapeutics, Inc.
Contact Us
Technology Transfer Office
1400 Jackson Street
Room 206b
Denver, CO 80206
Phone: (303) 3981262
E-mail: ip@njhealth.org